Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF), a multifunctional cytokine, potently stimulates angiogenesis including tumor neovascularization. Although well established in solid tumors, the role of VEGF in bone marrow neoangiogenesis and paracrine tumor-stromal cell interactions in lymphohematopoietic malignancies has not been fully elucidated. In multiple myeloma (MM), marrow neovascularization parallels disease progression. This parallel prompted us to investigate the expression and secretion of VEGF by myeloma cells and its potential effects in myeloma-marrow stroma interactions. The biologically active splice variants VEGF165 and VEGF121 were expressed and secreted by myeloma cell lines and plasma cells isolated from the marrow of patients with MM. As shown by immunocytochemistry or RT-PCR, myeloma cells did not express or weakly expressed the VEGF receptors FLT-1 and FLK-1/KDR, indicating that autocrine stimulation is unlikely. In contrast, FLK-1/KDR was abundantly expressed by marrow stromal cells. Therefore, we studied the effects of VEGF on marrow stroma, focusing on the secretion of interleukin-6 (IL-6), a potent growth factor for myeloma cells and an inhibitor of plasma cell apoptosis. Exposure of stromal and microvascular endothelial cells to recombinant human (rh) VEGF165 or VEGF121 induced a time- and dose-dependent increase in IL-6 secretion (14- to 27-fold at 50 ng/mL after 24 hours, P < .001). Conversely, rhIL-6 stimulated VEGF expression and secretion in myeloma cell lines (40%-60%; P < .05) and to a variable degree (up to 5.3-fold; P < .005) in plasma cells purified from the marrow of patients with MM. This mutual stimulation suggests paracrine interactions between myeloma and marrow stromal cells triggered by VEGF and IL-6.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Nonparametric Statistics for the Behavioral Sciences
Guitton, H., & Siegel, S. (1958) · Revue économique · doi:10.2307/3498751 · Cited by 35,245
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Vascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483
The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor
de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., & Williams, L. T. (1992) · Science · doi:10.1126/science.1312256 · Cited by 2,016
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
Terman, B. I., Dougher-Vermazen, M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., & Böhlen, P. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)90483-2 · Cited by 1,519
The implications of angiogenesis for the biology and therapy of cancer metastasis
Fidler, I. (1994) · Cell · doi:10.1016/0092-8674(94)90187-2 · Cited by 1,098
Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor
Cohen, T., Nahari, D., Cerem, L. W., Neufeld, G., & Levi, B.-Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.736 · Cited by 1,039
Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H., & Sato, M. (1990) · PubMed · Cited by 960
Klein, B., Zhang, X., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M., & Bataille, R. (1989) · Blood · doi:10.1182/blood.v73.2.517.517 · Cited by 763
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Hallek, M., Leif Bergsagel, P., & Anderson, K. C. (1998) · Blood · doi:10.1182/blood.v91.1.3 · Cited by 752
Bone marrow angiogenesis and progression in multiple myeloma
Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F., & Dammacco, F. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb08304.x · Cited by 630
Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F., & Dammacco, F. (1999) · Blood · doi:10.1182/blood.v93.9.3064 · Cited by 599
Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T., & Anderson, K. (1996) · Blood · doi:10.1182/blood.v87.3.1104.bloodjournal8731104 · Cited by 563
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.
Bellamy, W. T., Richter, L., Frutiger, Y. M., & Grogan, T. M. (1999) · PubMed · Cited by 559
Interleukin-6 in human multiple myeloma
Klein, B., Zhang, X., Lu, Z., & Bataille, R. (1995) · Blood · doi:10.1182/blood.v85.4.863.bloodjournal854863 · Cited by 520
Bataille, R., Jourdan, M., Zhang, X. G., & Klein, B. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114392 · Cited by 479
Plate, K. H., Breier, G., Weich, H. A., Mennel, H. D., & Risau, W. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590415 · Cited by 463
Fiedler, W., Graeven, U., Ergün, S., Verago, S., Kilic, N., Stockschläder, M., & Hossfeld, D. K. (1997) · Blood · doi:10.1182/blood.v89.6.1870 · Cited by 437
Aoki, Y., Jaffe, E. S., Chang, Y., Jones, K., Teruya-Feldstein, J., Moore, P. S., & Tosato, G. (1999) · Blood · doi:10.1182/blood.v93.12.4034 · Cited by 427
Angiogenesis in Bladder Cancer: Relationship Between Microvessel Density and Tumor Prognosis
Bochner, B. H., Cote, R. J., Weidner, N., Groshen, S., Chen, S.-C., Skinner, D. G., & Nichols, P. W. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.21.1603 · Cited by 420
Uchiyama, H., Barut, B., Mohrbacher, A., Chauhan, D., & Anderson, K. (1993) · Blood · doi:10.1182/blood.v82.12.3712.3712 · Cited by 418
(1996) · PubMed · Cited by 415
Bataille, R., & Harousseau, J.-L. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706053362307 · Cited by 389
Brock, T. A., Dvorak, H. F., & Senger, D. R. (1991) · PubMed · Cited by 321
Human Vascular Permeability Factor
Connolly, D. T., Olander, J. V., Heuvelman, D., Nelson, R., Monsell, R., Siegel, N., Haymore, B. L., Leimgruber, R., & Feder, J. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)47212-8 · Cited by 284
Rafii, S., Shapiro, F., Rimarachin, J., Nachman, R., Ferris, B., Weksler, B., Moore, M., & Asch, A. (1994) · Blood · doi:10.1182/blood.v84.1.10.10 · Cited by 281
Chauhan, D., Kharbanda, S., Ogata, A., Urashima, M., Teoh, G., Robertson, M., Kufe, D. W., & Anderson, K. C. (1997) · Blood · doi:10.1182/blood.v89.1.227 · Cited by 272
Interleukin-6 Inhibits Apoptosis of Malignant Plasma Cells
Lichtenstein, A., Tu, Y., Fady, C., Vescio, R., & Berenson, J. (1995) · Cellular Immunology · doi:10.1006/cimm.1995.1076 · Cited by 271
Interleukin-6 prevents dexamethasone-induced myeloma cell death
Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Barlogie, B., Xiao, H., & Epstein, J. (1994) · Blood · doi:10.1182/blood.v84.9.3063.3063 · Cited by 262
Yaccoby, S., Barlogie, B., & Epstein, J. (1998) · Blood · doi:10.1182/blood.v92.8.2908 · Cited by 255
Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells
Urashima, M., Ogata, A., Chauhan, D., Hatziyanni, M., Vidriales, M., Dedera, D., Schlossman, R., & Anderson, K. (1996) · Blood · doi:10.1182/blood.v87.5.1928.1928 · Cited by 235
'Role of bone marrow stromal cells in the growth of human multiple myeloma
Caligaris-Cappio, F., Bergui, L., Gregoretti, M., Gaidano, G., Gaboli, M., Schena, M., Zallone, A., & Marchisio, P. (1991) · Blood · doi:10.1182/blood.v77.12.2688.2688 · Cited by 234
Response patterns of purified myeloma cells to hematopoietic growth factors
Anderson, K., Jones, R., Morimoto, C., Leavitt, P., & Barut, B. (1989) · Blood · doi:10.1182/blood.v73.7.1915.1915 · Cited by 219
Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis
Claffey, K. P., & Robinson, G. S. (1996) · Cancer and Metastasis Reviews · doi:10.1007/bf00437469 · Cited by 194
Cornali, E., Zietz, C., Benelli, R., Weninger, W., Masiello, L., Breier, G., Tschachler, E., Albini, A., & Stürzl, M. (1996) · Europe PMC (PubMed Central) · Cited by 186
Cytokine regulation of interleukin 6 production by human endothelial cells
Shalaby, M. R., Waage, A., & Espevik, T. (1989) · Cellular Immunology · doi:10.1016/0008-8749(89)90036-1 · Cited by 167
The Development of a Model for the Homing of Multiple Myeloma Cells to Human Bone Marrow
Urashima, M., Chen, B. P., Chen, S., Pinkus, G. S., Bronson, R. T., Dedera, D. A., Hoshi, Y., Teoh, G., Ogata, A., Treon, S. P., et al. (1997) · Blood · doi:10.1182/blood.v90.2.754 · Cited by 159
Lokhorst, H., Lamme, T., de Smet, M., Klein, S., de Weger, R., van Oers, R., & Bloem, A. (1994) · Blood · doi:10.1182/blood.v84.7.2269.2269 · Cited by 159
The role of interleukin‐1 and tumour necrosis factor‐α in human multiple myeloma
Carter, A., Merchav, S., Silvian, I., & Tatarsky, I. (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb06330.x · Cited by 150
Cytokine Network in Human Multiple Myeloma
Klein, B., & Bataille, R. (1992) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30344-7 · Cited by 145
Nachbaur, D., Herold, M., Maneschg, A., & Huber, H. P. (1991) · Annals of Hematology · doi:10.1007/bf01714900 · Cited by 135
Vacca, A., Loreto, M. D., Ribatti, D., Stefano, R. D., Gadaleta‐Caldarola, G., Iodice, G., Caloro, D., & Dammacco, F. (1995) · American Journal of Hematology · doi:10.1002/ajh.2830500103 · Cited by 131
Krüssel, J.-S., Casañ, E. M., Raga, F., Hirchenhain, J., Wen, Y., Huang, H. Y., Bielfeld, P., & Polan, M. L. (1999) · Molecular Human Reproduction · doi:10.1093/molehr/5.5.452 · Cited by 111
Vacca, A., Ribatti, D., Iurlaro, M., Albini, A., Minischetti, M., Bussolino, F., Pellegrino, A., Ria, R., Rusnati, M., Presta, M., et al. (1998) · International Journal of Clinical & Laboratory Research · doi:10.1007/s005990050018 · Cited by 86
Interleukin-6 dependence of advanced malignant plasma cell dyscrasias
Zhang, X., Bataille, R., Widjenes, J., & Klein, B. (1992) · Cancer · doi:10.1002/1097-0142(19920315)69:6<1373::aid-cncr2820690612>3.0.co;2-1 · Cited by 83
The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.
Grigorieva, I., Thomas, X., & Epstein, J. (1998) · PubMed · Cited by 81
Kim, I. K., Uchiyama, H., Chauhan, D., & Anderson, K. C. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb08302.x · Cited by 70
Lagneaux, L., Delforge, A., Dorval, C., Bron, D., & Stryckmans, P. (1993) · Blood · doi:10.1182/blood.v82.8.2379.2379 · Cited by 66
Role of interleukin 6 in the growth of myelomaderived cell lines
Barut, B., Zon, L. I., Cochran, M. K., Paul, S. R., Chauhan, D., Mohrbacher, A., Fingeroth, J. D., & Anderson, K. C. (1992) · Leukemia Research · doi:10.1016/0145-2126(92)90073-g · Cited by 66
Serum interleukin‐6 (IL‐6) and interleukin‐4 (IL‐4) in patients with multiple myeloma (MM)
Kyrstsonis, M., ssis, G. D., evanis, C. B., lou, M. S., & Maniatis, A. G. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.d01-1491.x · Cited by 52
Thomas, X., Anglaret, B., Magaud, J., Epstein, J., & Archimbaud, E. (1998) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199809059251 · Cited by 46
Cited by
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
NF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892
Metadata
- Authors
- Dankbar, B., Padró, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R. M., Serve, H., Berdel, W. E., & Kienast, J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2000-04-15
- Volume
- 95
- Issue
- 8
- Pages
- 2630-2636
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1580184585
- Cited by
- 566
- References
- 56
- FWCI
- 22.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.